



IRA e-bulletin

Newsletter For Health Professionals in Rheumatology

From the
Editor's
Desk



Latest
Research



Expert
Opinion



Conference
Calendar



IRA
Matters



News from
EULAR 2013



Do You
Know?



Latest Research

- 13** In a cohort of polymyositis/dermatomyositis, treatment with I.V. pulse cyclophosphamide was associated with improvement; the therapeutic response was sustained in majority of the patients.

Efficacy and Limitations of Pulse Cyclophosphamide Therapy in Polymyositis and Dermatomyositis.

Nagappa M, *et al. J Clin Neuromuscul Dis.* 2013;14(4):161–168.

[Read More →](#)

- 14** Of men receiving zoledronic acid, 1.6% developed new vertebral fractures during 2-year follow-up, compared with 4.9% of those receiving placebo.

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Steven Boonen, *et al. N Engl J Med.* 2012;367:1714–1723.

[Read More →](#)

- 15** Patients with early, active axial SpA who received IFX+NPX combination treatment were twice as likely to achieve clinical remission as patients who received NPX alone. NPX alone led to clinical remission in one third of patients.

Efficacy and Safety of Infliximab plus Naproxen versus Naproxen Alone in Patients with Early, Active Axial Spondyloarthritis: Results from the Double-Blind, Placebo-Controlled INFAST Study, Part 1.

Sieper J, *et al. Ann Rheum Dis.* 2013 May 21. [Epub ahead of print]

[Read More →](#)

- 16** In axial SpA patients who reached partial remission after treatment with either IFX+NPX or NPX alone, disease activity remained low, and about half of patients remained in remission during 6 months.

Maintenance of Biologic-free Remission with Naproxen or no Treatment in Patients with Early, Active Axial Spondyloarthritis: Results from a 6-month, Randomised, Open-label Follow-up Study, INFAST Part 2.

Sieper J, *et al. Ann Rheum Dis.* 2013 Jun 5. [Epub ahead of print]

[Read More →](#)

